Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autogene cevumeran - Genentech

Next Previous
Drug Profile

Autogene cevumeran - Genentech

Alternative Names: BNT-122; BNT122/RO7198457; Individualized Neoantigen Specific immunotherapy; iNeST; IVAC_M_uID; PCV RO7198457; Personalized cancer vaccine RO7198457; RG-6180; RG6180-1; RO-719845; RO-7198457

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; Genentech; Memorial Sloan-Kettering Cancer Center; Roche
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Colorectal cancer; Malignant melanoma; Urogenital cancer
  • No development reported Pancreatic cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 10 Mar 2026 BioNTech terminates phase II IMCODE004 trial in Urogenital cancer (Combination therapy, Adjuvant therapy) in Australia, the US, Argentina, Belgium, Canada, Denmark, France, Germany, Greece, Italy, South Korea, Mexico, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, the United Kingdom (IV), due to business decision(NCT06534983)
  • 03 Nov 2025 Efficacy and adverse events data from a phase II trial in Malignant melanoma released by BioNTech
  • 17 Oct 2025 Efficacy and Immunogenicity data from a phase II trial in Malignant melanoma presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top